SA521422733B1 - مشتقات 1-((2-(2,2,2-تراي فلورو إيثوكسي) بيريدينـ-4-ـيل) ميثيل) kcnq يوريا كمقويات لـ - Google Patents
مشتقات 1-((2-(2,2,2-تراي فلورو إيثوكسي) بيريدينـ-4-ـيل) ميثيل) kcnq يوريا كمقويات لـInfo
- Publication number
- SA521422733B1 SA521422733B1 SA521422733A SA521422733A SA521422733B1 SA 521422733 B1 SA521422733 B1 SA 521422733B1 SA 521422733 A SA521422733 A SA 521422733A SA 521422733 A SA521422733 A SA 521422733A SA 521422733 B1 SA521422733 B1 SA 521422733B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- protection element
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801716P | 2019-02-06 | 2019-02-06 | |
| US201962811038P | 2019-02-27 | 2019-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521422733B1 true SA521422733B1 (ar) | 2024-02-08 |
Family
ID=69743945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521422733A SA521422733B1 (ar) | 2019-02-06 | 2021-08-05 | مشتقات 1-((2-(2,2,2-تراي فلورو إيثوكسي) بيريدينـ-4-ـيل) ميثيل) kcnq يوريا كمقويات لـ |
Country Status (23)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7451543B2 (ja) * | 2019-02-06 | 2024-03-18 | イーライ リリー アンド カンパニー | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 |
| JP2023531500A (ja) | 2020-06-25 | 2023-07-24 | イドーシア ファーマシューティカルズ リミテッド | シクロブチル－ウレア誘導体 |
| WO2023054626A1 (ja) * | 2021-09-30 | 2023-04-06 | 住友ファーマ株式会社 | シクロプロパンアミド誘導体 |
| AU2022390453B2 (en) * | 2021-11-19 | 2026-03-19 | Angelini Pharma S.P.A. | Novel heteroaryl-urea compounds as kv7.2 inhibitors |
| JP2024540583A (ja) | 2021-11-19 | 2024-10-31 | アイカジェン・エルエルシー | Ｋｖ７．２エンハンサーとしてのピリジン化合物 |
| CN118510757A (zh) | 2021-12-22 | 2024-08-16 | 伊卡根有限责任公司 | 环丙基化合物 |
| WO2023158584A1 (en) | 2022-02-15 | 2023-08-24 | Icagen, Llc | New bicyclopentane derivatives |
| IT202200024948A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio KV7.2/KV7.3 |
| IT202200024963A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0971892A1 (en) * | 1997-03-25 | 2000-01-19 | Astra Pharmaceuticals Limited | Novel pyridine derivatives and pharmaceutical compositions containing them |
| CN100345823C (zh) * | 2003-01-14 | 2007-10-31 | 赛特凯恩蒂克公司 | 化合物、组合物及方法 |
| EP1737852A2 (en) | 2004-04-13 | 2007-01-03 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| EP1781635B1 (en) * | 2004-07-29 | 2012-06-13 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| WO2010036316A1 (en) * | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| CA2763786C (en) * | 2009-06-08 | 2014-09-30 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| CA2828456C (en) * | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| CN103709097A (zh) * | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
| BR112015022263B1 (pt) * | 2013-03-15 | 2023-01-03 | Deciphera Pharmaceuticals Llc | N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica |
| AU2015223049B2 (en) * | 2014-02-27 | 2019-03-21 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| SG11201703284XA (en) * | 2014-10-24 | 2017-06-29 | Ono Pharmaceutical Co | Kcnq2-5 channel activator |
| JP6943239B2 (ja) * | 2016-04-22 | 2021-09-29 | 小野薬品工業株式会社 | Ｋｃｎｑ２〜５チャネル活性化剤 |
| JP7451543B2 (ja) * | 2019-02-06 | 2024-03-18 | イーライ リリー アンド カンパニー | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 |
-
2020
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 HU HUE20709409A patent/HUE064734T2/hu unknown
- 2020-02-04 ES ES20709409T patent/ES2968807T3/es active Active
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 IL IL285113A patent/IL285113B2/en unknown
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 PL PL20709409.5T patent/PL3921030T3/pl unknown
- 2020-02-04 KR KR1020217028040A patent/KR102924196B1/ko active Active
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
- 2020-02-04 AU AU2020218180A patent/AU2020218180B2/en active Active
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en not_active Ceased
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 SM SM20240003T patent/SMT202400003T1/it unknown
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 CN CN202080012797.0A patent/CN113692304B/zh active Active
-
2021
- 2021-08-05 SA SA521422733A patent/SA521422733B1/ar unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US12344584B2/en active Active
-
2024
- 2024-03-06 JP JP2024033668A patent/JP2024063191A/ja not_active Withdrawn
-
2025
- 2025-05-27 US US19/219,238 patent/US20250282725A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009396A (es) | Derivados de 1 - ((2- (2,2,2-trifluoroetoxi) piridin-4-yl) metil) urea como potenciadores kcnq. | |
| MXPA05012840A (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades. | |
| NO952178L (no) | Katekol-dietere som selektive PDEIV inhibitekorer | |
| YU81091A (sh) | Analozi 5-(1-hidroksi-2-piperidinopropil)-2-(1h,3h)-indolona | |
| ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| MX2022011534A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa. | |
| WO2007104783A3 (en) | 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators | |
| TW200633982A (en) | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| NO20070484L (no) | Sammenspleisede pyrimidinderivater og sammensetninger derav som CXCR3 reseptormodulatorer, anvendbare ved forebygging og behandling av inflammatoriske og immunregulatoriske lidelser og sykdommer. | |
| TW200505903A (en) | CGRP receptor antagonists | |
| RS79504A (sr) | Derivati aminoindazola, postupak izrade i međuproizvodi ovog postupka kao medicinski produkti i farmaceutske kompozicije koje ih sadrže | |
| MA27926A1 (fr) | Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1 | |
| JP2017533968A5 (cg-RX-API-DMAC10.html) | ||
| TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| EP1689713A4 (en) | BENZYL ETHER AND BENZYLAMINE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| EP2091328A4 (en) | SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| PH12022551394A1 (en) | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof | |
| MX2025012347A (es) | Compuestos heterociclicos y usos de estos | |
| MX2025000985A (es) | Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas | |
| HK1255438A1 (zh) | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 | |
| MX2023011829A (es) | Derivados de uracilo como inhibidores de trpa1. | |
| NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| SA523440367B1 (ar) | مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1 |